TRAININGS BY BMC OBAT TTA+

Please click here to register

X-WAIVER TRAININGS

Live Training Dates First Option:

1/27/2022 (Part 1) 8am-12pm ET 2/3/2022 (Part 2) 8pm-12pm ET

Intended Audience

These X-Waiver Trainings are open to all Providers, Participants must attend both Part 1 and 2 in order to receive completion certificate.

Second Option:

2/26/2022 (Part 1) 8am-12pm ET 3/5/2022 (Part 2) 8am-12pm ET

Please click here to register and learn more about the requirements of the training.

PCSS website link: www.pcssNOW.ora Contact information: pcss@aaap.org AAAP is the DATA 2000 sponsor for this training









Clinical Support







Funding for this initiative was made possible (in part) by grant no. 1H79Tl081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Educational Objectives:

- Review the identification of opioid use disorder (OUD) and evidence-based treatments.
- · Discuss the pharmacology of opioids as it relates to treatment of OUD patients.
- Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
- Explain the process of buprenorphine induction as well as stabilization and maintenance.
 Discuss other approved antagonist and agonist medications to treat OUD.
- Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.
- Review the appropriate treatment of pain in the OUD patient.
- Recognize the importance of obtaining appropriate licensing for treating patients with OLID



Joint Accreditation Statement: In support of improving patient care, this activity has been planned and implemented by the American Academy of Addiction Psychiatry. Boston Medical Center Grayken Center for Addiction, Massachusetts Department of Health, and Bureau of Substance Addiction Services. American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Designation Statement: American Academy of Addiction Psychiatry designates this live course for a maximum of 8 (eight) AMA PRA Category 1 Credits**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Designation Statement: American Academy of Addiction Psychiatry is an approved provider of nursing continuing education through AAAP's Joint Accreditation provider # 4008192. This program is approved for up to 8 Nursing Contact Hours.



PA Designation Statement:

American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 8 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.